Snapshot · The Peter Attia Drive
Anti-amyloid therapies like lecanemab and donanemab show only 0.3–0.4 point improvements on the 18-point CDR Sum of Boxes scale, a modest but potentially meaningful shift.
Where this was said
At 56:32 · chapter starts 51:45
The three FDA-approved anti-amyloid monoclonal antibodies — aducanumab (withdrawn), lecanemab, and donanemab — all clear amyloid plaques from the brain, but their clinical benefit on the 18-point CDR Sum of Boxes scale is only 0.3–0.4 points compared to placebo, a small but potentially meaningful effect that Gayatri Devi believes is larger when treatment is earlier [1] — Gayatri Devi "Anti-amyloid monoclonal antibodies like lecanemab and donanemab can clear amyloid from the brain, but carry a greater than 40% risk of ARIA…" 52:58 . The most serious risk is ARIA — brain edema and hemorrhage caused by the antibodies disrupting amyloid-laden artery walls — which exceeds 40% in standard protocols for APOE4 homozygotes. Her ultra-slow titration protocol reduces ARIA to roughly 4% in published data from her practice. However, insurance companies refuse to reimburse off-protocol dosing for lecanemab, meaning patients who want the safer protocol must pay out of pocket — a systemic barrier she describes with visible frustration. Donanemab's approved titration schedule is more flexible, allowing her to implement slow escalation without insurance conflict.
Aducanumab was approved in 2021 against its FDA advisory board's recommendation because clearing amyloid didn't translate to clear clinical benefit in the trials. Gayatri Devi prescribed it anyway, applying a simple personal test: would she want it herself if she had Alzheimer's? Her answer was yes.
Anti-amyloid monoclonal antibodies like lecanemab and donanemab can clear amyloid from the brain, but carry a greater than 40% risk of ARIA in standard protocols for APOE4 carriers. Gayatri Devi developed an ultra-slow titration protocol that reduces this risk to approximately 4%, allowing even high-risk APOE4 homozygotes to access potentially life-changing therapy.
Aducanumab carried a greater than 40% incidence of abnormal brain bleeding and swelling (ARIA), driving Gayatri Devi to develop her slow-titration protocol.
Gayatri Devi's slow-titration protocol for APOE4 carriers on anti-amyloid monoclonal antibodies yields only a 4% rate of ARIA, far below standard protocols.
Mental health challenges are nearly universal — BetterHelp's own research found the majority of Americans experiencing symptoms right now.
When applying for Medicaid to cover nursing home costs, there is a 5-year look-back period that can disqualify applicants who gave away or spent down assets.
A broken pipe filled the Bad Friends studio with what the hosts identified as hydrogen sulfide — microscopic fecal aeroparticles — that the crew denied smelling.
Fei-Fei Li's father's liver surgery performed by a da Vinci robot resulted in 10 times less blood loss than a typical open liver surgery, thanks to laparoscopic precision.
Approximately 115 million adults in the US currently have prediabetes, most of whom are unaware, according to the Lingo sponsor segment.
Drug overdose deaths in the US fell from 110,000 to 80,000 in 2024, and then to roughly 70,000 — the largest single-year drop the CDC has ever recorded.
Men's overdose death rate fell 27% in a single year, outpacing the 23% drop for women.
The steepest decline in overdose deaths was among 15–24-year-olds, whose rate fell 37%.
Fei-Fei Li observed that on a given hospital shift, nurses walk miles just to fetch medicine and supplies, illustrating a clear use case for assistive robotics in healthcare.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.